TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04978623

Intervention type: OTHER
Intervention: high frequency ultrasound
Description: high frequency ultrasound in subgroups of patients with CIDP, anti-MAG, NMMBC and L-S syndrome

Intervention type: OTHER
Intervention: high frequency ultrasound
Description: high frequency ultrasound in subgroups of patients with CIDP, anti-MAG, NMMBC and L-S syndrome

Intervention type: OTHER
Intervention: high frequency ultrasound
Description: high frequency ultrasound in subgroups of patients with CIDP, anti-MAG, NMMBC and L-S syndrome

Intervention type: OTHER
Intervention: high frequency ultrasound
Description: high frequency ultrasound in subgroups of patients with CIDP, anti-MAG, NMMBC and L-S syndrome
Study: NCT04632199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 111In-IPN01087 Low dose
Description: Administered once via slow intravenous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 111In-IPN01087 High dose
Description: Administered once via slow intravenous injection.
Study: NCT04901507

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Voutia System
Description: Participants will wear the Voutia System oral irrigation device continuously through the day and night, removing for cleaning and if otherwise necessary, but not for time extending beyond six-eight hours.
Study: NCT02723435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Given PO
Study: NCT05241639

Intervention type: DIAGNOSTIC_TEST
Intervention: Pentacam
Description: Pentacam (Oculus GmbH, Wetzlar, Germany) is used to image both the anterior and posterior corneal surfaces, providing a complete pachymetry map. Furthermore, it includes the corneal densitometry program in its software, which detects the amount of backscattered light in different regions of the cornea, providing an objective assessment of corneal transparency, and it is hypothesized that corneal densitometry may be altered in the presence of a systemic inflammatory disease, even in the absence of any corneal haze or scar

Intervention type: DIAGNOSTIC_TEST
Intervention: Pentacam
Description: Pentacam (Oculus GmbH, Wetzlar, Germany) is used to image both the anterior and posterior corneal surfaces, providing a complete pachymetry map. Furthermore, it includes the corneal densitometry program in its software, which detects the amount of backscattered light in different regions of the cornea, providing an objective assessment of corneal transparency, and it is hypothesized that corneal densitometry may be altered in the presence of a systemic inflammatory disease, even in the absence of any corneal haze or scar

Intervention type: DIAGNOSTIC_TEST
Intervention: Pentacam
Description: Pentacam (Oculus GmbH, Wetzlar, Germany) is used to image both the anterior and posterior corneal surfaces, providing a complete pachymetry map. Furthermore, it includes the corneal densitometry program in its software, which detects the amount of backscattered light in different regions of the cornea, providing an objective assessment of corneal transparency, and it is hypothesized that corneal densitometry may be altered in the presence of a systemic inflammatory disease, even in the absence of any corneal haze or scar
Study: NCT05452707

Intervention type: OTHER
Intervention: Observation and questionnaire of active therapy
Description: There will be an observation of the usual care; no intervention will be added.

Intervention type: OTHER
Intervention: Observation and questionnaire of active therapy
Description: There will be an observation of the usual care; no intervention will be added.
Study: NCT05959005

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention.
Study: NCT05019976

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation - Dose Level 0
Description: Dose Per Fraction (Each Radiation Treatment): 3.2Gy to 2.4Gy (minimal dose) depending on what study doctor prescribes~Total Dose of Radiation for Treatment Period: 44.8Gy to 33.6Gy (minimal dose) depending on what study doctor prescribes~Total Number of Radiation Treatments: 14

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation - Dose Level 1
Description: Dose Per Fraction (Each Radiation Treatment): 4.2Gy to 3.2Gy (minimal dose) depending on what study doctor prescribes~Total Dose of Radiation for Treatment Period: 42Gy to 32Gy (minimal dose) depending on what study doctor prescribes~Total Number of Radiation Treatments: 10

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation - Dose Level 2
Description: Dose Per Fraction (Each Radiation Treatment): 5.2Gy to 4.2Gy (minimal dose) depending on what study doctor prescribes~Total Dose of Radiation for Treatment Period: 39.2Gy to 29.4Gy (minimal dose) depending on what study doctor prescribes~Total Number of Radiation Treatments: 7

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation - Dose Level 3
Description: Dose Per Fraction (Each Radiation Treatment): 6.8Gy to 5.4Gy (minimal dose) depending on what study doctor prescribes~Total Dose of Radiation for Treatment Period: 34Gy to 27Gy (minimal dose) depending on what study doctor prescribes~Total Number of Radiation Treatments: 5

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation - Dose Level 4
Description: Dose Per Fraction (Each Radiation Treatment): 10Gy to 7.8Gy (minimal dose) depending on what study doctor prescribes~Total Dose of Radiation for Treatment Period: 30Gy to 23.4Gy (minimal dose) depending on what study doctor prescribes~Total Number of Radiation Treatments: 3
Study: NCT05495295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PhOx430
Description: A standard 3 + 3 design will be followed. PhOx430 will be administered orally twice a day (bid), at a 12-hour interval, continuously in cycles of 21 days. At each dose level (DL), three patients will be included and the first patient will be observed for at least 21 days before enrolling the following two. Three additional patients will be enrolled at each DL if a DLT is observed in the first three patients.~A maximum of 4 increasing Dose Levels are foreseen (10, 20, 40 and 70 mg/kg/day), and PhOx430 will be administered in two doses at a 12-hour interval.
Study: NCT06334133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadisegliatin 800 mg QD
Description: Cadisegliatin is an orally bioavailable small-molecule glucokinase activator.
Study: NCT06447376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: Single dose of prophylactic siltuximab, 11mg/kg, started 1 hour prior (+/- 60 minutes) to the infusion of epcoritamab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Epcoritamab dosing for Diffuse Large B-cell Lymphoma Participants:~* Cycle 1, Day 1 = 0.16mg~* Cycle 1, Day 8 = 0.8mg~* Cycle 1, Day 15 = 48mg~* Cycle 1, Day 22 = 48mg~* Cycles 2 \& 3, Day 1 = 48mg~* Cycles 2 \& 3, Day 8 = 48mg~* Cycles 2 \& 3, Day 15 = 48mg~* Cycles 2 \& 3, Day 22 = 48mg~* Cycles 4-9, Day 1 = 48mg~* Cycles 4-9, Day 15 = 48mg~* Cycle 10+ , Day 1 = 48mg~Epcoritamab dosing for Follicular Lymphoma Participants:~* Cycle 1, Day 1 = 0.16mg~* Cycle 1, Day 8 = 0.8mg~* Cycle 1, Day 15 = 3mg~* Cycle 1, Day 22 = 48mg~* Cycle 2 \& 3, Day 1 = 48mg~* Cycle 2 \& 3, Day 8 = 48mg~* Cycle 2 \& 3, Day 15 = 48mg~* Cycle 2 \& 3, Day 22 = 48mg~* Cycle 4-9, Day 1 = 48mg~* Cycle 4-9, Day 15 = 48mg~* Cycle 10+ , Day 1 = 48mg
Study: NCT06334133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadisegliatin 800 mg BID
Description: Cadisegliatin is an orally bioavailable small-molecule glucokinase activator.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05681728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: On Day 1 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion
Study: NCT05573360

Intervention type: OTHER
Group type: OTHER
Intervention: NGF4-B test formulation
Description: One drop of investigational product instilled on the eye

Intervention type: OTHER
Group type: OTHER
Intervention: NGF4-B test formulation
Description: One drop of investigational product instilled on the eye

Intervention type: OTHER
Group type: OTHER
Intervention: NGF4-B test formulation
Description: One drop of investigational product instilled on the eye

Intervention type: OTHER
Group type: OTHER
Intervention: NGF4-B test formulation
Description: One drop of investigational product instilled on the eye

Intervention type: OTHER
Group type: OTHER
Intervention: NGF4-B test formulation
Description: One drop of investigational product instilled on the eye

Intervention type: OTHER
Group type: OTHER
Intervention: NGF6-B test formulation
Description: One drop of investigational product instilled on the eye
Study: NCT05681728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion
Study: NCT04207710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gebauer's Pain Ease Top Aerosol Mist Spray
Description: Topical refrigerant spray
Study: NCT05573360

Intervention type: OTHER
Group type: OTHER
Intervention: NGF6-B test formulation
Description: One drop of investigational product instilled on the eye

Intervention type: OTHER
Group type: OTHER
Intervention: NGF6-B test formulation
Description: One drop of investigational product instilled on the eye

Intervention type: OTHER
Group type: OTHER
Intervention: NGF6-B test formulation
Description: One drop of investigational product instilled on the eye

Intervention type: OTHER
Group type: OTHER
Intervention: NGF6-B test formulation
Description: One drop of investigational product instilled on the eye
Study: NCT04207710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gebauer's Pain Ease Top Aerosol Mist Spray
Description: Topical refrigerant spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gebauer's Ethyl Chloride
Description: Topical refrigerant spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gebauer's Ethyl Chloride
Description: Topical refrigerant spray
Study: NCT05573360

Intervention type: OTHER
Group type: OTHER
Intervention: NGF6-E test formulation
Description: One drop of investigational product instilled on the eye

Intervention type: OTHER
Group type: OTHER
Intervention: NGF6-E test formulation
Description: One drop of investigational product instilled on the eye
Study: NCT05922683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vivomixx
Description: Vivomixx (a mixture of Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subspecies bulgaricus, Streptococcus salivarius subspecies thermophiles, Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis), as VivomixxAll consenting participants will be randomized into the treatment to control arm, receiving either Vivomixx or a placebo for 8 weeks.~During the study, women will visit the healthcare center or vice-versa on a bi-weekly basis to receive sachets of Vivomixx or a placebo according to their trial arm.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CapScan®
Description: The only non-standard sample collection instrument is the CapScan device. The CapScan Collection Capsule (Capsule) is a non-invasive device that collects gastrointestinal samples along the GI tract that are then analyzed outside the body. Samples collected by the Capsule will be expressed, then undergo DNA sequencing and mass spectrometric analysis to determine the identity and function of the bacterial and host cells in the different regions of the GI tract and compared to similar analyses conducted on concomitantly collected stool samples.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CapScan®
Description: The only non-standard sample collection instrument is the CapScan device. The CapScan Collection Capsule (Capsule) is a non-invasive device that collects gastrointestinal samples along the GI tract that are then analyzed outside the body. Samples collected by the Capsule will be expressed, then undergo DNA sequencing and mass spectrometric analysis to determine the identity and function of the bacterial and host cells in the different regions of the GI tract and compared to similar analyses conducted on concomitantly collected stool samples.
Study: NCT05573360

Intervention type: OTHER
Group type: OTHER
Intervention: NGF6-E test formulation
Description: One drop of investigational product instilled on the eye
Study: NCT04870320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endeavor: Computer-Based Cognitive Stimulation Intervention
Description: Endeavor application will be utilized by participant on iPad

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Words!: Computer-Based Cognitive Stimulation Intervention
Description: Words! application will be utilized by participant on iPad

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life (QOL) Questionnaires
Description: Standardized QOL questionnaire will be administered at each study visit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Life (QOL) Questionnaires
Description: Standardized QOL questionnaire will be administered at each study visit
Study: NCT04019015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prothrombin Complex Concentrate, Human
Description: Prothrombin Complex Concentrate (PCC) prepared from human plasma and contains blood coagulation factors

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline solution
Study: NCT05329025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: QL1706 will be administered by IV infusion at 5mg/kg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: QL1706 will be administered by IV infusion at 5mg/kg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
Study: NCT05615454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bio-electromagnetic energy regulation therapy (BEMER) machine model type: B.BOX CLASSIC, model NO: 420100, 12-15 Volt, (BEMER Int.AG, Liechtenstein product).
Description: The experimental group (receive the BEMER therapy) for five sessions/week for three weeks. Plus, pelvic floor exercise.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo BEMER
Description: Comparison group (receive placebo BEMER therapy) for five sessions/week for three weeks. Plus, pelvic floor exercise.
Study: NCT05573360

Intervention type: OTHER
Group type: OTHER
Intervention: NGF6-E test formulation
Description: One drop of investigational product instilled on the eye

Intervention type: OTHER
Group type: OTHER
Intervention: NGF6-E test formulation
Description: One drop of investigational product instilled on the eye

Intervention type: OTHER
Group type: OTHER
Intervention: Systane eye drop
Description: One drop of commercial product instilled on the eye

Intervention type: OTHER
Group type: OTHER
Intervention: Systane eye drop
Description: One drop of commercial product instilled on the eye

Intervention type: OTHER
Group type: OTHER
Intervention: Systane eye drop
Description: One drop of commercial product instilled on the eye

Intervention type: OTHER
Group type: OTHER
Intervention: Systane eye drop
Description: One drop of commercial product instilled on the eye

Intervention type: OTHER
Group type: OTHER
Intervention: Systane eye drop
Description: One drop of commercial product instilled on the eye
Study: NCT04914000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help Materials
Description: Self-help booklet targeted by cancer type to increase smoking cessation motivation
Study: NCT05887804

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord-derived mesenchymal stem cells (UC-MSC)
Description: Group 1 was injected UC-MSC 2 million cells/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord-derived mesenchymal stem cells conditioned medium (UC-CM)
Description: Group 2 was injected UC-CM 1 mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide (TA)
Description: Group 3 was injected TA 40 mg/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
Study: NCT05987618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral appliance with elastic bands
Description: The elastic bands are attached to hooks on both the upper and lower appliance, and on both sides. The elastic bands will be carefully selected not to interfere with retention of the oral appliance. The strongest elastic bands that do not interfere with retention of the oral appliance will be chosen, probably within the range of 85-170 grams (3/8 - 3/16).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oral appliance without elastic bands
Description: The oral appliance without the elastic bands.
Study: NCT05121246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB05 (Proposed palivizumab biosimilar)
Description: Single IM dose of 3 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-Synagis®
Description: Single IM dose of 3 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-Synagis®
Description: Single IM dose of 3 mg/kg
Study: NCT05006612

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Anterior Plane Block
Description: SAPB Technique; U/S probe will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, Then, using U/S guidance, A 38-mm 22-gauge regional block needle is advanced in-plane at an angle of approximately 45 degrees towards the fifth rib. After aspiration to avoid IV injection 30ml of levobupivacaine 0.25% is injected anteriorly to the rib and deep to the serratus anterior muscle.~SAPB combined with Modified Pectoral Nerve Block :~SAPB with injection of 20 ml levobupivacaine 0.25% as discussed before. Modified Pectoral Nerve Block:After identification of the axillary vessels, the U/S probe will turned inferolaterally till the serratus anterior and the two pectoralis muscles are detected in one plane. 10 ml of levobupivacaine 0.25%was injected between the two pectoralis muscles. After that,10 mL of levobupivacaine 0.25%is injected above this muscle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Anterior Plane Block
Description: SAPB Technique; U/S probe will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, Then, using U/S guidance, A 38-mm 22-gauge regional block needle is advanced in-plane at an angle of approximately 45 degrees towards the fifth rib. After aspiration to avoid IV injection 30ml of levobupivacaine 0.25% is injected anteriorly to the rib and deep to the serratus anterior muscle.~SAPB combined with Modified Pectoral Nerve Block :~SAPB with injection of 20 ml levobupivacaine 0.25% as discussed before. Modified Pectoral Nerve Block:After identification of the axillary vessels, the U/S probe will turned inferolaterally till the serratus anterior and the two pectoralis muscles are detected in one plane. 10 ml of levobupivacaine 0.25%was injected between the two pectoralis muscles. After that,10 mL of levobupivacaine 0.25%is injected above this muscle.
Study: NCT06028815

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group music therapy
Description: Music therapy intervention using active and receptive techniques, focusing on the technique of songwriting.
Study: NCT05814029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization with movement for Ankle
Description: The participant will assume a lunge position on a rigid serving table with the relevant extremity in a weight-bearing stance and the foot in a neutral position. An inelastic belt will be placed around the clinician's waist, flush with the lower edge of the medial malleolus, around the distal tibia and fibula. The clinician will stabilize the talus and forefoot with the web spacing of the hands and pressure dimensions on the talus and forefoot, and maintain posterior to anterior sliding of the tibia over the talus using the arch. The clinician will continue to apply pressure while the person is reporting discomfort and/or while the lunge moves, which will continue until the end of the range of motion. Mobilization will be performed as a 3 set of 10 repetitions.
Study: NCT05019560

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: IFT response, hemodynamics and BIS value were recorded during intubation period. Then the data acquisition was stopped and the isolated forearm cuff deflated. IFT values were noted by two independent observers

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TIVA
Description: IFT response, hemodynamics and BIS value were recorded during intubation period. Then the data acquisition was stopped and the isolated forearm cuff deflated. IFT values were noted by two independent observers
Study: NCT05547711

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: drawing blood
Description: drawing blood annually measurement of heartrate variability annually determine weight with a bioimpedance scale

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: drawing blood
Description: drawing blood annually measurement of heartrate variability annually determine weight with a bioimpedance scale
Study: NCT05579535

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gait training exercises
Description: walking exercises in different directions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gait training exercises
Description: walking exercises in different directions
Study: NCT05840133

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention was required for patients or control group in this study
Description: The patient was treated normally and no intervention was required in this study
Study: NCT05840133

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention was required for patients or control group in this study
Description: The patient was treated normally and no intervention was required in this study

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention was required for patients or control group in this study
Description: The patient was treated normally and no intervention was required in this study